When European CDMOs consider expanding to Japan, LinkedIn often feels like the obvious starting point for outreach. After all, in Europe and North America, LinkedIn has become the lifeblood of business development, recruiting, and thought leadership. Yet in Japan, many companies discover the hard way that simply replicating their global LinkedIn strategy does not yield results.
LinkedIn in Japan: The Numbers Tell the Story
LinkedIn remains a niche platform in Japan. As of spring 2025, there are just over five million users—only about four percent of the total population. By comparison, the United States has LinkedIn penetration of more than 30% of its population, while in Germany and France the figure is around 15–20%. This contrast underscores how limited LinkedIn’s reach is in Japan relative to other major pharma markets.
The users who are active on LinkedIn in Japan tend to be globally minded professionals or people who deliberately seek an international presence. This is useful if you want to reach progressive, English-speaking managers—but it’s only one segment of the pharmaceutical decision-maker universe. Many Japanese executives, especially those in mid-size or traditional pharma companies, will not be found on LinkedIn at all.
Cultural Friction: Why LinkedIn Feels Awkward in Japan
Beyond numbers, culture plays a central role. In Europe, LinkedIn is almost mandatory: over half of companies actively use it for recruitment and communication. In Japan, by contrast, there are cultural barriers. Self-promotion feels uncomfortable. Sharing professional achievements publicly may clash with norms of modesty. The result is that many Japanese business developers and executives avoid the platform or use it passively.
During CPhI Europe, for instance, many Japanese BD representatives exchanged business cards and engaged in meaningful discussions, yet none of them were connected on LinkedIn afterward. For Europeans, this seems like a missed opportunity—but in Japan, it is simply how professional networking works.
I have also seen more subtle cultural signals. For example, I once came across a senior Japanese executive who had registered on LinkedIn but used a photo of a cat as the profile picture. It was clear that the individual did not fully understand the platform’s norms, and this reflects how LinkedIn still feels unfamiliar or awkward to many professionals in Japan. In addition to platform literacy, there is also a generational element: for older executives, there can be a sense of embarrassment or discomfort about showing their own face publicly online, which further reduces the appeal of LinkedIn.
Why Alternatives Aren’t True Alternatives
There are Japanese-born platforms like Eight, which digitizes business cards, or Wantedly, which focuses on career opportunities for younger professionals. But these do not serve as full-fledged alternatives to LinkedIn. Their reach is limited, and they do not create the same ecosystem for international B2B engagement. In practice, there is no Japanese equivalent that can replace what LinkedIn does globally.
This means CDMOs must accept the reality: relying solely on LinkedIn will not deliver comprehensive exposure in Japan.
What Actually Works
So if LinkedIn is not enough, where should pharma CDMOs focus?
First, recognize that Japanese pharma networks are rooted in community, not platforms. Industry associations like JPLA (Japan Pharmaceutical Licensing Association) or Link-J (Life Science Innovation Network Japan) are where relationships take shape. JPLA, for instance, organizes four meetings per year where BD professionals from innovator and generic companies, from large corporations to biotechs and academia, all gather together. All sessions are conducted in Japanese, and without entering such communities, it is very difficult to gain access to the Japanese BD ecosystem. This makes JPLA a crucial gateway for any foreign CDMO hoping to build meaningful connections. Participating in their events and contributing to discussions signals long-term commitment more strongly than posting on LinkedIn ever could.
Second, trade shows matter more than online engagement. BioJapan, CPhI Japan, and Interphex are not optional add-ons; they are the centerpieces of business development. A presence there—whether through your own booth or via a trusted partner—gives you visibility in a way no digital ad campaign can replicate.
Finally, localized visibility is key. Japanese-language press releases, thought leadership articles in domestic trade media, and consistent communication through channels like PR Times help demonstrate seriousness and credibility. These efforts reach audiences that LinkedIn cannot.
The Role of LinkedIn—But With Realistic Expectations
Does this mean LinkedIn is useless in Japan? Not at all. It is still the best place to connect with globally oriented executives and to maintain visibility with your international contacts who influence Japan-related decisions. But it is only a partial solution.
For CDMOs, the real strategy is a hybrid one: use LinkedIn as a bridge to global-facing leaders while simultaneously investing in the networks, events, and media that Japanese pharma professionals actually pay attention to. By doing so, you cover both ends of the spectrum—those who are already international and those who never set foot on LinkedIn.
Bottom line: If your Japanese LinkedIn strategy feels broken, it’s because it was never designed for Japan in the first place. Success comes from integrating local networks, events, and communication channels into your market entry plan—while keeping LinkedIn in its rightful, limited role.